Medchemexpress LLC Ergolide | 54999-07-4 | 5 MG

Supplier:  Medchemexpress LLC HYN68935MG

Ergolide is an orally active dual inhibitor targeting NF-κB/p65 and NLRP3. It blocks the NF-κB signaling pathway, inhibits p65 nuclear translocation, and prevents inflammasome assembly by binding to the NACHT domain of NLRP3. This leads to reduced inflammatory mediators, cytokine production, and induction of cancer cell apoptosis, autophagy, and ROS generation. It also enhances the anti-tumor effect of vincristine and improves outcomes in models of acute lung injury and sepsis.

• Dual inhibitor for NF-κB/p65 and NLRP3.
• Inhibits inflammasome assembly.
• Reduces inflammation and promotes apoptosis in cancer cells.
• Enhances anti-tumor efficacy of vincristine.
• Beneficial in models of acute lung injury and sepsis.
• Research applications include uveal melanoma, neurodegenerative diseases, and acute lymphoblastic leukemia.
• Purity: 99.48%.

Catalog No. 50-004-20023